OncoVista Innovative Therapies, Inc. is a biopharmaceutical company that was incorporated on January 8, 1999. The company is engaged in developing and commercializing cancer therapies through the development of proprietary products as well as the acquisition of rights to technologies and drugs from others. OncoVista's product pipeline consists of advance (Phase 2) and early (Phase 1) clinical-stage compounds, late pre-clinical drug candidates and early pre-clinical leads.
The Company's therapeutic strategy is based on targeting the patient's tumors using tumor-associated biomarkers. Their products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin was OncoVista's first clinical-stage development compound. It depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for it's therapeutic activity.
The L-nucleoside conjugate technology works by selectively targeting certain cancer cell characteristics. This makes cancer cells vulnerable to the actions of the drug, but leaves healthy cells unaffected. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity. It has shown tumor growth inhibitory activity in human colon, breast, and prostate tumors growing in animal models.
Principal Research Scientist and Project Leader
Documentaries, videos and podcasts
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.